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The human homologue of mouse double minute 2 (MDM2) is overexpressed in tumors and contributes to
tumorigenesis through inhibition of p53 activity. We investigated the effect of the anti-estrogen fulve-
strant on MDM2 expression and sensitivity of estrogen receptor positive human breast cancer cell lines
to chemotherapeutics. Fulvestrant down-regulated MDM2 through increased protein turnover. Fulve-
strant blocked estrogen-dependent up-regulation of MDM2 and decreased basal expression of MDM2
in the absence of estradiol. As combinations of fulvestrant with doxorubicin, etoposide or paclitaxel were
synergistic, altering cell cycle distribution and increasing cell death, this provides rationale for testing
combinatorial chemotherapy with fulvestrant as a novel therapeutic strategy for patients with advanced
breast cancer.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Fulvestrant, a newer type of estrogen receptor (ER) antagonist
that lacks estrogen agonist effect and cross-resistance with other
hormonal agents, is currently used in clinic to treat patients with
ER positive (ER+), advanced and metastatic breast cancers. Fulve-
strant downregulates intracellular ER levels and results in abroga-
tion of estrogen-sensitive gene transcription. One of the genes
whose expression is upregulated in response to estrogen is mouse
double minute 2 (MDM2), ﬁrst identiﬁed as an oncoprotein
encoded by double minute chromosomes in murine sarcoma cells,
and later found to be overexpressed in a variety of human can-
cers. Hdm2 represents the human ortholog (hereafter in this
report, the human ortholog is denoted as MDM2). Transcriptional
activation of MDM2 by estrogen is mediated via an estrogen
response element in breast cancer cells homozygous or heterozy-
gous for the single nucleotide polymorphism in the MDM2 pro-
moter (SNP 309) [1].MDM2 mainly acts as a negative regulator of p53 activity, thus
prohibiting cells from entering into cell cycle arrest, senescence, or
apoptosis. In addition, MDM2 also plays a regulatory role in cell-
cycle progression independent of p53. For instance, MDM2 pro-
motes the degradation of the phosphorylated retinoblastoma pro-
tein (pRB) [2] and p21 [3], thereby modulating their activities.
MDM2 also interacts with the S-phase promoting factor E2F1 and
increases its function [4]. Due to its ability to determine the fate
of critical regulators of cell cycle, the activity and expression of
MDM2 have been shown to affect the sensitivity of cancer cells
to chemotherapeutic agents [5,6].
In the current study, we sought to determine whether the
anti-estrogenic agent, fulvestrant, could suppress MDM2 expres-
sion and enhance the response of breast cancer cells to treat-
ment with standard chemotherapeutic drugs. Our study shows
that treatment of ER+ breast cancer cells with fulvestrant
resulted in increased turnover and down-regulation of MDM2
protein, and sensitized tumor cells to chemotherapeutic drugs
doxorubicin, etoposide, and paclitaxel. These results suggest that
combined use of fulvestrant with these cytotoxic drugs may
enhance effectiveness of chemotherapy in patients with ER+
breast cancers.
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2.1. Cell lines and culture
T47D and MCF7 breast cancer cell lines (ATCC, Manassas, VA) were maintained
in RPMI 1640 (Invitrogen Life Technologies, Grand Island, NY) supplemented with
10% FBS, 100 units/ml penicillin and 100 lg/ml streptomycin at 37 C in a
humidiﬁed atmosphere containing 5% CO2/95% air. For estrogen and anti-estrogen
treatments, cells were cultured in phenol red-free RPMI supplemented with char-
coal-stripped 10% fetal bovine serum for 48 h prior to drug treatment.2.2. Reagents and antibodies
Doxorubicin hydrochloride (DOX), etoposide (VP-16), paclitaxel (TAX), and
fulvestrant (Fulv) (Sigma Aldrich, St. Louis, MO) were dissolved in DMSO. b-Estra-
diol–water soluble (Sigma Aldrich, St. Louis, MO) was dissolved in water. Primary
antibodies used for Western blotting and immunoprecipitation were as follows:
MDM2 (SMP14), ERa (HC-20), p53 (DO-1), (Santa Cruz Biotechnology, Dallas, TX);
p21 (Ab-1), (EMD Millipore, Billerica, MA); monoclonal anti-b-actin clone AC-15
(Sigma Aldrich, St. Louis, MO); PARP, caspase-8 (1C12) (Cell Signaling, Danvers,
MA). Proteins were visualized using enhanced chemiluminescence (ECL) detection
(Pierce Biotechnology Inc., Rockford, IL). Senescence was detected using senescence
b-Galactosidase Staining Kit (Cell Signaling, Danvers, MA).2.3. Real-time RT–PCR
Cells plated in 6-well plates were treated with fulvestrant as indicated. Total
RNA was extracted from treated cells with RNeasy Mini Kit (QIAGEN, Germantown,
MD) and quantiﬁed by UV absorbance spectroscopy. Two-step quantitative RT–PCR
was performed as follows: (1) cDNA synthesis was performed using TaqMan
Reverse Transcription Kit (Life Technologies, Grand Island, NY). The thermal proﬁle
for cDNA synthesis was 25 C for 10 min, 48 C for 30 min, and 95 C for 5 min. (2)
Quantitative PCR was performed using TaqMan gene expression assays for MDM2
(Hs00242813_m1) and GAPDH (endogenous control) (Hs99999905_m1). Quantita-
tive PCR ampliﬁcations were performed on the Applied Biosystems 7900 HT Fast
Real Time PCR system. Reactions were carried out in 20 ll volume containing
10 ll of 2 TaqMan Universal PCR Master Mix (Life Technologies, Grand Island,
NY). The thermal proﬁle for real-time PCR was 50 C for 2 min, then 95 C for
10 min followed by 40 cycles at 95 C for 15 s and 60 C for 1 min. The threshold
cycle (CT) values were determined.2.4. Western blot analysis
Cell lysates were prepared using the CelLytic™ MT Cell Lysis Reagent (Sigma
Aldrich, St. Louis, MO) with Protease Inhibitor Cocktail. Lysates were clariﬁed by
centrifugation at 12,000g for 30 min at 4 C. Protein concentration was determined
by the Bradford method using the Bio-Rad protein assay reagent (Bio-Rad, Hercules,
CA). Lysates (10–50 lg proteins) were separated onto 8% SDS–PAGE gels followed
by transfer to nitrocellulose membranes. Membranes were incubated in blocking
solution consisting of 5% powered milk in PBST (PBS plus 0.1% Tween 20) at room
temperature for 1 h, then immunoblotted with the indicated primary antibody
overnight at 4 C. Detection by enzyme-linked chemiluminescence was performed
according to the manufacturer’s protocol (ECL; Pierce Biotechnology Inc., Rockford,
IL). Quantiﬁcation of protein bands was performed using ImageJ software (http://
rsb.info.nih.gov/ij).2.5. Co-Immunoprecipitation
T47D cells were plated in 100-mm dishes. After the respective treatment (ful-
vestrant 1 lM for 16 h or vehicle), cells were washed twice with ice-cold PBS,
scraped off the dishes and pelleted at 1500g for 5 min. Cell pellets were then lysed
in NETN buffer [50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 0.1% IGEPAL CA-630
(Sigma Aldrich, St. Louis, MO), 1 mM EDTA, and Protease Inhibitor Cocktail (Sigma
Aldrich, St. Louis, MO)] for 30 min at 4 C in a rotating wheel. Lysates were clariﬁed
by centrifugation at 16,000g for 20 min at 4 C. Protein concentration was deter-
mined by Bradford assay and equal protein amounts were pre-cleared with Protein
A/G Plus-Agarose beads (Santa Cruz Biotechnology, Dallas, TX) for 1 h at 4 C. Pre-
cleared lysates were then incubated with MDM2 (SMP14) antibody or mouse IgG
for 6 h at 4 C. Protein A/G Plus-Agarose beads were added and incubated overnight
at 4 C. Beads were then washed ﬁve times with lysis buffer containing 0.5% of IGE-
PAL and one time with PBS and boiled with 2 Laemmli sample buffer. Pre-cleared
lysates prior to immunoprecipitation served as input controls. Extracted proteins
were loaded onto a 4–15% SDS–PAGE gradient gel followed by transfer to PVDF
membrane. Blots were assayed for the expression of MDM2, ERa, and b-actin (load-
ing control).2.6. Cycloheximide treatment
Cells were treated with vehicle or 1 lM of fulvestrant for 16 h, and then pulse-
chased for MDM2 protein in the presence of 20 lg/ml of cycloheximide (CHX). Cell
extracts from the treated cells collected at the indicated times were analyzed by
Western blotting.
2.7. Drug sensitivity assay
Cells were plated in 96-well tissue culture plates, allowed to attach for 5–6 h,
and then treated with different drug combinations for 66 h. Fifty microliters of
2.5 mg/ml 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) (Sigma Aldrich, St. Louis, MO) in PBS were then added to each well, and cells
were incubated at 37 C for 4 h. Formazan crystals were dissolved in DMSO. Absor-
bance was determined at 570 nm using a Wallac 1420 Victor3 plate reader (Perkin
Elmer, Waltham, MA). Viability was expressed as a percentage of control by divid-
ing the absorbance of each treated sample by the average of the untreated controls.
Combination index (CI) for drug interaction (e.g., synergy) was calculated using the
CompuSyn software (ComboSyn, Inc.). CI values at different effect and dose levels
and isobolograms were generated using this software.
2.8. Cell cycle analysis
Cells were plated in 6 well tissue culture plates and treated with different drug
combinations for 72 h. After treatment, all cells were harvested, and cell number
was determined using the Vi-CELL Cell Viability Analyzer (Beckman Coulter, India-
napolis, IN). A single cell suspension with equal cell number was prepared for each
sample. Cells were ﬁxed with absolute ethanol dropwise while vortexing and incu-
bated overnight. Fixed cells were washed twice with 1X PBS and stained with stain-
ing solution (10 lg/ml propidium iodide and 100 lg/ml RNase A in PBS (Sigma
Aldrich, St. Louis, MO). Cell cycle distribution was analyzed by ﬂow cytometry
(Cytomics FC 500 Series; Beckman Coulter, Indianapolis, IN). The data were ana-
lyzed using CXP software (Beckman Coulter, Indianapolis, IN).
2.9. Senescence assay
Cells were plated in 12 well tissue culture plates and treated with different drug
combinations for 72 h. Cells were washed with 1X PBS, and ﬁxed for 15 min per
manufacturers instructions. Cells were then washed twice with 1X PBS. b-Galacto-
sidase staining solution (pH 6.0) was added to the cells for overnight incubation.
Stained and unstained cells from three representative ﬁelds were counted.
2.10. Statistical analysis
For estrogen and anti-estrogen treatments, Student’s t-test was used to calcu-
late the P value of the difference between control and treated cells from three inde-
pendent experiments where a P value of less than 0.05 was considered statistically
signiﬁcant. For drug combination effects on cell cycle, apoptosis protein markers,
and senescence, Student’s t-test and one way ANOVA were used to calculate the
P value between treatments from three independent experiments where a P value
of less than 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Treatment with fulvestrant down-regulates MDM2 protein in
human breast cancer cells
To test the effect of anti-estrogen on the expression of MDM2,
the ER+ human breast cancer cell lines, MCF7 and T47D, were trea-
ted with different concentrations of fulvestrant and then MDM2
protein expression measured. Fig. 1A and B show that fulvestrant
treatment caused a signiﬁcant decrease in MDM2 protein expres-
sion in both cell lines and that the reduction of MDM2 correlated
with the decrease in ER expression. Treatment of MCF7 and T47D
cells with estradiol increased MDM2 expression. However, fulve-
strant not only reduced basal MDM2 expression (in the absence
of estradiol), but also blocked the up-regulation of MDM2 induced
by estradiol (Fig. 1C and D).
3.2. p53 Activity is not affected by fulvestrant
Because MDM2 is a p53-regulated gene and there are known
interactions between ER and p53, the potential role of p53 in
MDM2 down-regulation with fulvestrant was investigated. The
Fig. 1. Fulvestrant decreases MDM2 protein expression and abolishes the effect of estradiol on MDM2 expression. MCF7 (A) and T47D (B) cells were cultured in the presence
of different concentrations of fulvestrant (Fulv) for 66 h. ER and MDM2 were detected by Western blot and normalized to b-actin. The decrease in protein expression (shown
relative to vehicle control treatment) after fulvestrant treatment was calculated for each drug concentration. P < 0.05 compared to vehicle control treatment. MCF7 (C) and
T47D (D) cells were cultured in the presence of different concentrations of estradiol (E2) for 72 h, with or without fulvestrant. MDM2 protein level was measured by Western
blot and normalized to b-actin. P < 0.05 compared to corresponding E2 treatment without fulvestrant. Representative Western blots of MCF7 and T47D lysates from three
independent experiments are shown below the corresponding graphs.
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with different concentrations of fulvestrant and p53 expression
measured (Fig. 2). MDM2 depletion by fulvestrant did not correlate
with an increase in p53, as might have been expected according to
the regulatory role of MDM2 on p53. Instead a slight though not
signiﬁcant decrease in p53 was observed. In addition, activation
of p53 was not affected by fulvestrant as measured by expression
of p21, a gene that is tightly controlled by p53. Fulvestrant did
not alter levels of p21.3.3. Fulvestrant treatment does not alter MDM2 mRNA level
To determine whether the down-regulation of MDM2 caused by
fulvestrant resulted from altered transcription of MDM2 gene,
MDM2 mRNA in MCF7 and T47D cells treated with vehicle or ful-
vestrant was measured using quantitative PCR. This was performed
at both 16 and 66 h for several concentrations of fulvestrant in
both MCF7 and T47D cells. The shorter time period was chosen
as fulvestrant treatment can affect multiple transcriptional
Fig. 2. MDM2 depletion by fulvestrant does not correlate with p53 expression or activation. MCF7 cells (wild-type for p53) were cultured in the presence of different
concentrations of estradiol (E2) for 72 h, with or without fulvestrant (Fulv). The p53 (A) and p21 (B) protein levels were measured by Western blot and normalized to the
levels of b-actin. No signiﬁcant changes were observed. (C) Representative Western blots from three independent experiments are shown.
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vestrant at 66 h (Fig. 1A and B), mRNA levels are unchanged or
slightly increased for both cells lines (Fig. 3A and B). Similar pat-
terns were noted at 16 h treatment with fulvestrant in both cell
lines (Fig. 3A and B). These results suggest that fulvestrant does
not suppress transcription of MDM2 gene.3.4. Fulvestrant treatment does not disrupt the ERa–MDM2 complex
ERa is known to interact with other proteins. As fulvestrant
results in decreased ERa as well as reduced MDM2 levels, co-
immunoprecipitation was performed to identify ERa–MDM2 pro-
tein interactions. T47D cells were cultured with or without 1 lM
of fulvestrant for 16 h after which immunoprecipitation was per-
formed (Fig. 3C). Western blot of input protein (pre-clearedFig. 3. Fulvestrant does not reduce MDM2 mRNA abundance or disrupt the ERa–MDM
concentrations of fulvestrant (Fulv) for 66 h (gray bars) or 16 h (black bars). MDM2 mRN
were determined by quantitative PCR (qPCR), and the quantiﬁcation data were analyze
control) levels. No signiﬁcant changes were observed. (C) T47D cells were cultured with
MDM2 was performed. IP for mouse IgG served as an isotype-matched negative control
and ERa. Input lanes conﬁrm the decrease in ERa expression as a result of fulvestrant t
fulvestrant treatment. As expected, no protein is detectable in mouse IgG IP lanes.lysates) conﬁrmed reduced expression of ERa as a function of ful-
vestrant treatment, i.e. there was an 80% decrease in ERa expres-
sion. As expected, MDM2 was present in both MDM2
immunoprecipitation lanes with and without fulvestrant treat-
ment (Fig. 3C). MDM2 was also present in the input lanes when
a longer exposure was done (data not shown). In both samples
with and without drug treatment, ERa was immunoprecipitated
with MDM2. This suggests that an ERa–MDM2 complex remains
intact with fulvestrant treatment.3.5. Fulvestrant increases the turnover rate of MDM2 protein
As fulvestrant seemed to directly affect the protein levels of
MDM2 without down-regulating the mRNA levels of this gene,
the effect of fulvestrant on MDM2 protein half-life was evaluated.2 complex. MCF7 (A) and T47D (B) cells were cultured in the presence of different
A levels were evaluated at two different fulvestrant treatment times. mRNA levels
d following the delta delta Ct method after normalization to GAPDH (endogenous
or without 1 lM of fulvestrant for 16 h after which immunoprecipitation (IP) for
for non-speciﬁc interactions. Western blot was done to assess expression of MDM2
reatment (decrease of 80%). ERa is detected in MDM2 IP lanes with and without
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cells treated with fulvestrant or vehicle, in order to determine
the effect of this anti-estrogen on stability of MDM2 protein. The
pulse-chase experiments demonstrated that fulvestrant facilitated
degradation of MDM2 protein, as reﬂected in the shortened half-
life of this protein in the presence of fulvestrant (27 min vs.
42 min in T47D cells; 80 min vs. 180 min in MCF7 cells) (Fig. 4).
Thus, down-regulation of MDM2 expression by fulvestrant
appeared to be attributable to enhanced MDM2 turnover that
was unrelated to ERa–MDM2 protein interaction.
3.6. Fulvestrant enhances the sensitivity of human breast cancer cells
to chemotherapeutic drugs
Inhibition of MDM2 has been reported to potentiate cytotoxic
effects of chemotherapeutic drugs such as paclitaxel [5]. Therefore,
using MCF7 and T47D breast cancer cell lines, it was evaluated
whether down-regulation of MDM2 by fulvestrant could enhance
the effectiveness of cytotoxic drugs that are commonly used for
treatment of breast cancer. Dose-response studies of doxorubicin,
paclitaxel or etoposide in combination with fulvestrant were per-
formed, and the data from MTT assays were analyzed using the
CompuSyn software. CompuSyn analyses showed that combined
use of doxorubicin, paclitaxel or etoposide with fulvestrant
resulted in different degrees of synergism in both of the breast can-
cer cell lines tested (Table 1, Fig. 5).
3.7. Combination of fulvestrant and chemotherapeutic drugs induces
altered cell cycle distribution, apoptosis, and senescence
Since the combination of fulvestrant with cytotoxic drugs was
synergistic, the mechanism of cell death was evaluated. MCF7Fig. 4. Fulvestrant reduces MDM2 protein half-life. T47D (A) and MCF7 (B) cells were cu
exposed to cycloheximide (CHX) for different incubation times. MDM2 protein was mea
T47D (C) and MCF7 (D) lysates are shown.and T47D cells were treated for 72 h with each drug or combined
at synergistic concentrations to assess cell cycle distribution, apop-
tosis, and senescence. A representative cell cycle histogram for
MCF7 treated with fulvestrant, etoposide, or the combination dem-
onstrates treatment-related alterations in cell cycle distribution
(Fig. 6A). Quantitative analysis of cell cycle alterations is shown
in Fig. 6B. A collective summary of cell cycle distribution for all
treatments is depicted in Table 2. Cell cycle analysis revealed that
fulvestrant increased the G1 population in both cell lines consis-
tent with induction of G1 arrest. In MCF7 cells, doxorubicin or eto-
poside alone induced G2/M arrest. While the combination of
fulvestrant and doxorubicin had a similar effect to doxorubicin
alone, the combination of fulvestrant and etoposide signiﬁcantly
increased the sub G1 population of cells compared to either agent
alone (Table 2, Fig. 6A and B). This suggests that the combination of
fulvestrant and etoposide more effectively induced cell cycle arrest
and apoptosis. Paclitaxel treatment of MCF7 and T47D cells
increased the sub G1 population. However, the combination of ful-
vestrant and paclitaxel increased both G2/M and sub G1 cell pop-
ulations (Table 2).
As measures of apoptosis, PARP and caspase 8 cleavage were
measured in MCF7 protein lysates by Western blotting. Doxorubi-
cin alone or in combination with fulvestrant signiﬁcantly increased
PARP cleavage (Fig. 6C). While fulvestrant or etoposide alone had
no effect on PARP cleavage, the combination induced signiﬁcant
cleavage as compared to control or to either agent alone
(Fig. 6C). Consistent with the increased sub G1 and G2/M popula-
tions, this suggests that the fulvestrant and etoposide combination
synergistically induces cell cycle arrest and apoptosis. As MCF7
cells are caspase 3 deﬁcient, caspase 8 cleavage was alternatively
assessed. Caspase 8 cleavage signiﬁcantly increased with fulve-
strant, doxorubicin, and paclitaxel without further enhanced effectltured with or without 1 lM of fulvestrant for 16 h. After drug treatment, cells were
sured by Western blot and normalized to b-actin. Representative Western blots of
Table 1
Combination of doxorubicin, paclitaxel or etoposide with fulvestrant results in different degrees of synergism.
Cell line Treatment Constant ratio CIa Effectb
MCF7c Fulvestrant:Doxorubicin 1:0.5 0.45; 0.63; 0.79 Syn, Syn 
1:0.015 0.34; 0.53; 0.84 Syn, Syn 
Fulvestrant:Paclitaxel 1:0.025 0.33; 0.71; 0.97 Syn/Add
1:0.0005 0.31; 0.47; 0.51 Syn, Syn
Fulvestrant:Etoposide 1:1 0.10; 0.15; 0.23 Syn, Syn
1:5 0.29; 0.32; 0.39 Syn, Syn
T47Dc Fulvestrant:Doxorubicin 1:0.25 0.68; 0.97; 1.04 Syn/Add
1:0.0035 0.71; 0.79; 0.98 Syn/Add
Fulvestrant:Paclitaxel 1:0.0125 0.82; 0.89; 1.56 Syn, Syn-/Ant
1:0.0002 0.71; 0.74; 3.02 Syn/Ant
Fulvestrant:Etoposide 1:10 0.89; 0.89; 0.96 Syn-/Add
1:0.07 0.69; 1.00; 1.32 Syn/Add/Ant
MCF7d Fulvestrant:Doxorubicin 1:0.5 0.76; 0.76; 0.95; 1.02 Syn/Add
Fulvestrant:Paclitaxel 1:0.025 0.15; 0.20; 0.76; 1.46 Syn/Ant
Fulvestrant:Etoposide 1:1 0.25; 0.36; 0.37; 1.22 Syn/Ant
T47Dd Fulvestrant:Doxorubicin 1:0.5 0.68; 0.96; 1.17; 1.37 Syn/Add/Ant
Fulvestrant:Paclitaxel 1:0.025 0.80; 1.49; 1.58; 2.57 Syn/Ant
Fulvestrant:Etoposide 1:1 1.33; 1.50; 7.57; 64.76 Ant
a CI: combination index.
b CI < 1 Synergism: Syn (slight: Syn-, moderate: Syn, synergism: Syn, strong: Syn, very strong: Syn). CI = 1 Additive effect: Add. CI > 1 Antagonism: Ant (slight: Ant-,
moderate: Ant, antagonism: Ant, strong: Ant, very strong: Ant).
c Analysis of combination effect at optimal doses for each cell line.
d Comparison of MCF7 and T47D response at the same constant ratios and doses.
Fig. 5. Isobolograms for combination treatment with fulvestrant and chemotherapy. Three different drug combinations at constant ratios were assessed for each cell line:
MCF7 (A), T47D (B). MTT assays were carried out and the results of the drug combination analysis using CompuSyn software are shown. Isobolograms from the three different
drug combinations for doxorubicin (Dox), paclitaxel (Tax), and etoposide (VP16) at two different constant ratios were assessed for each cell line and were used to calculate the
CI values listed in Table 1. CI: combination index. CI h1: synergism (Syn); CI = 1: additive effect (Add); CIi 1: antagonism (Ant).
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Fig. 6. Combination of fulvestrant and cytotoxic drugs induces altered cell cycle distribution, apoptosis, and senescence. MCF7 and T47D cells were treated for 72 h with
fulvestrant (Fulv), doxorubicin (Dox), paclitaxel (Tax), and etoposide (VP16) either alone or in combination. A representative histogram (A) and bar graph depiction (B) of
MCF7 cell cycle distribution are shown for fulvestrant, etoposide, or the combination of fulvestrant and etoposide. Quantitation of cell cycle distribution for all treatments is
shown in Table 2. (C) Levels of cleaved PARP and cleaved caspase 8 in MCF7 cells were analyzed by Western blot and normalized to full length PARP and caspase 8,
respectively. Representative Western blots of MCF7 lysates from three independent experiments are shown below the corresponding graph. (D) Senescence in MCF7 treated
cells was evaluated based on b-galactosidase staining. P < 0.05 compared to vehicle control treatment. P < 0.05 for combination treatments compared to each agent alone or
to control.
Table 2
Cell cycle distribution of MCF7 and T47D cells treated with cytotoxic drugs and fulvestrant alone or in combination.
Cell line Treatment % Sub G1 (s.d.)a % G1 (s.d.) % S (s.d.) % G2/M (s.d.)
MCF7 DMSO 0.1 (0.1) 60.4 (2.4) 11.5 (0.9) 26.0 (1.0)
Fulvb (50 lM) 0.5 (0.1) 88.5 (0.2) 1.0 (0.3) 9.1 (0.2)
Doxb (0.75 lM) 3.7 (0.5) 37.2 (0.61) 7.6 (0.4) 50.4 (0.1)
Fulv (50 lM) + Dox (0.75 lM) 2.4 (0.1) 40.4 (1.0) 12.1 (1.4) 44.2 (1.3)
Fulv (10 lM) 1.1 (0.4) 88.3 (0.9) 0.9 (0.2) 8.8 (0.3)
Taxb (5 nM) 39.5 (1.0) 21.9 (0.4) 15.0 (0.4) 18.5 (2.0)
Ful (10 lM) + Tax (5 nM) 26.8 (4.0) 18.3 (1.2) 15.0 (1.3) 37.2 (4.3)
Fulv (5 lM) 1.1 (0.2) 87.3 (1.0) 0.7 (0.1) 9.8 (0.9)
VP16b (5 lM) 2.4 (0.5) 27.7 (0.6) 9.4 (0.8) 58.8 (0.1)
Fulv (5 lM) + VP16 (5 lM) 10.5 (3.9) 29.9 (2.0) 8.9 (2.1) 48.6 (3.7)
T47D DMSO 0.7 (0.3) 66.7 (0.9) 8.4 (0.7) 23.0 (0.6)
Fulv (50 lM) 0.9 (0.1) 82.4 (1.4) 2.2 (0.5) 13.7 (0.9)
Dox (0.175 lM) 6.1 (0.6) 3.8 (0.4) 47.9 (4.2) 37.4 (3.5)
Fulv (50 lM) + Dox (0.175 lM) 1.7 (0.6) 37.9 (0.4) 32.4 (2.5) 26.1 (2.0)
Tax (10 nM) 42.7 (5.3) 16.9 (1.3) 13.2 (1.7) 23.7 (4.2)
Ful (50 lM) + Tax (10 nM) 15.8 (0.8) 30.0 (1.9) 8.5 (1.0) 43.0 (1.8)
VP16 (3.5 lM) 11.3 (1.4) 6.6 (0.5) 54.9 (0.7) 22.3 (1.4)
Fulv (50 lM) + VP16 (3.5 lM) 3.1 (0.9) 39.2 (1.0) 33.7 (1.8) 21.7 (1.3)
a s.d.: standard deviation.
b Fulv: fulvestrant; Dox: doxorubicin; Tax: paclitaxel; VP16: etoposide.
58 S.C. Dolﬁ et al. / Cancer Letters 350 (2014) 52–60from the combination (Fig. 6C). Etoposide and the combination
with fulvestrant showed a non-signiﬁcant trend to increased
cleaved caspase 8.Senescence, detected by b-galactosidase staining after 72 h drug
treatment, signiﬁcantly increased with fulvestrant, paclitaxel, eto-
poside, and their combination with fulvestrant as compared to
S.C. Dolﬁ et al. / Cancer Letters 350 (2014) 52–60 59control (Fig. 6D). Combination treatment was not signiﬁcantly dif-
ferent from either agent alone.4. Discussion
It was hypothesized that fulvestrant mediates its anti-tumor
effect through reduced estrogen-regulated MDM2 transcription.
This study demonstrates that fulvestrant reduces MDM2 expres-
sion through decreased MDM2 protein half-life and this is not
related to protein destabilization from altered ERa–MDM2 protein
interactions.
Resistance to endocrine therapy and chemotherapy has been a
critical issue in the treatment of ER+ breast cancers. Clinical and
preclinical studies evaluating the combination of fulvestrant with
other agents to elicit improved therapeutic response have shown
conﬂicting results for drug interaction studies [7–15], though ful-
vestrant appears to act as a radiosensitizer [16]. It was hypothe-
sized that blocking expression of MDM2 with anti-estrogen
would restore sensitivity to chemotherapeutic drugs in ER+ breast
cancer cell lines. These data demonstrate that fulvestrant exerts
synergistic effects in combination with several chemotherapeutic
drugs, consistent with a recent report showing in vivo synergism
between fulvestrant and doxorubicin or docetaxel [17]. In support
of these synergistic effects are the enhanced cell death mecha-
nisms of apoptosis and sensecence, as well as altered cell cycle dis-
tribution that were observed. Interestingly, though low dose
paclitaxel alone produces prolonged mitotic arrest followed by tri-
polar mitosis [18] as evidenced by the appearance of a wide sub G1
peak, addition of fulvestrant accelerates the movement of the cells
into G2/M arrest with a population of cells in sub G1.
The therapeutic mechanism of fulvestrant is thought to be due
to classic reduction in ERa and its resultant reduction in estrogen-
regulated gene expression. Numerous studies have identiﬁed asso-
ciations between MDM2 and ERa expression in breast tissue and
breast cancer cell lines as the ﬁrst intron of MDM2 contains an
estrogen response element [19–25]. As many estrogen regulated
genes are pro-survival, reduced gene expression could contribute
to the effectiveness of fulvestrant. However, alternative mecha-
nisms of regulation of ER-associated genes have clinical relevance
including the novel role for MDM2 in regulating cell adhesion and
cell motility through endosomal targeting of proteins [26]. The
mechanism supports observations correlating MDM2 expression
with breast cancer stage and outcomes [27–30].
This study describes a novel effect of fulvestrant on altered pro-
tein stability. In contrast to the lack of ERa-mediated effect on
MDM2 protein half-life, MDM2 has been demonstrated to regulate
ERa turnover through their direct interaction, and MDM2 ubiqui-
tin-ligase activity with targeted ERa degradation and transactiva-
tion [31,32]. This occurs through direct interaction with ERa and
p53 in a ternary complex both in the absence or presence of estro-
gens. MDM2 exerts its effects both dependent on and independent
of p53. In this study, fulvestrant-induced reduction in both ERa and
MDM2 is independent of p53 expression and is consistent with that
of Brekman et al. [24] showing that estrogen-induced breast cancer
cell proliferation required a p53-independent role of MDM2.
In summary, this study demonstrates that fulvestrant possesses
a suppressive effect on MDM2 expression and that this may con-
tribute mechanistically to the observed synergistic effect with che-
motherapeutic drugs and fulvestrant in ER+ human breast cancer
cells. Cytotoxic drug-fulvestrant combinations demonstrating
additive or synergistic interactions should be further evaluated in
in vivo models for breast cancer to determine their effectiveness.
These results provide a rationale and support for testing the
combination of fulvestrant with chemotherapy as a novel thera-
peutic strategy for patients with advanced breast cancers.5. Conﬂict of Interest
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